Compass Therapeutics Inc. (CMPX), a clinical-stage, oncology-focused biopharmaceutical company, has a clinical trial catalyst related to its lead drug candidate Tovecimig in patients with advanced biliary tract cancer, to watch this quarter.
Tovecimig is designed to simultaneously block Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to tumor blood vessel formation.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.